摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-1-氟-2-丙胺盐酸盐 | 458560-63-9

中文名称
(S)-1-氟-2-丙胺盐酸盐
中文别名
——
英文名称
(S)-1-methyl-2-fluoroethylamine hydrochloride
英文别名
(S)-(2-fluoro-1-methylethyl)amine hydrochloride;(S)-1-fluoropropan-2-amine hydrochloride;(S)-1-fluoro-2-propylamine hydrochloride;(2S)-1-fluoropropan-2-amine hydrochloride;(2S)-1-fluoro-2-propylamine hydrochloride;(2S)-1-fluoropropan-2-amine;hydrochloride
(S)-1-氟-2-丙胺盐酸盐化学式
CAS
458560-63-9
化学式
C3H8FN*ClH
mdl
MFCD22196467
分子量
113.563
InChiKey
FHXAJBGANRCCBG-DFWYDOINSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    123-124 °C

计算性质

  • 辛醇/水分配系数(LogP):
    -0.01
  • 重原子数:
    6
  • 可旋转键数:
    1
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    26
  • 氢给体数:
    2
  • 氢受体数:
    2

制备方法与用途

(S)-1-氟-2-丙胺盐酸盐用作研究用化合物。

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] APOPTOSIS SIGNAL-REGULATING KINASE INHIBTOR<br/>[FR] INHIBITEUR DE LA KINASE RÉGULANT LE SIGNAL APOPTOTIQUE
    申请人:GILEAD SCIENCES INC
    公开号:WO2018169742A1
    公开(公告)日:2018-09-20
    Provided is a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in treatment of non-alcoholic steatohepatitis, alcoholic hepatitis, pulmonary arterial hypertension, heart failure with preserved ejection fraction, and diabetic kidney disease. Also provided are amorphous and crystalline forms of the compound of Formula (I) and salts, co-crystals, solvates, and hydrates thereof.
    提供了一种化合物Formula (I)或其药用可接受的盐,用于治疗非酒精性脂肪性肝炎、酒精性肝炎、肺动脉高压、保留射血分数心力衰竭和糖尿病肾病。还提供了Formula (I)化合物的非晶形和晶形以及其盐、共晶、溶剂合物和合物。
  • Fluoroamines via Chiral Cyclic Sulfamidates
    作者:Jeffrey J. Posakony、Timothy J. Tewson
    DOI:10.1055/s-2002-25766
    日期:——
    N-benzyl [1,2,3]-oxathiazolidine 2,2-dioxides (cyclic sulfamidates) were synthesized from their corresponding β-amino alcohols and used as substrates in fluorination reactions with tetrabutylammonium fluoride (TBAF). After desulfonation of the intermediates, the N-benzyl fluoroamines were debenzylated by transfer hydrogenolysis with Pd/C to yield (S) and (R)-2-amino-1-fluoropropanes (2b and 3b, respectively, both with 95% ee). The reactions were carried out on multi-gram scale without the need for chromatographic purification of the intermediates. In the presence of carbonate, the (S)- and (R)-N-benzylfluoroamines underwent intramolecular cyclizations in which fluoride was displaced to yield cyclic carbamates 13 and 14.
    N-苄基[1,2,3]-噻唑烷-2,2-二氧化物(循环磺酰胺酸酯)是由相应的β-基醇合成的,并用作与四丁基氟化铵(TBAF)进行化反应的底物。在中间体去磺化后,通过与Pd/C的转移氢解反应去除苄基,生成(S)和(R)-2-基-1-丙烷(分别为2b和3b,两者的ee均为95%)。这些反应是在多克级规模上进行的,无需对中间体进行色谱纯化。在碳酸盐存在的情况下,(S)-和(R)-N-苄基胺发生分子内环化反应,离子被取代,生成循环碳酸酯13和14。
  • ANTIBACTERIAL COMPOUNDS
    申请人:Forge Therapeutics, Inc.
    公开号:US20210221796A1
    公开(公告)日:2021-07-22
    Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. Furthermore, the subject compounds and compositions are useful for the treatment of bacterial infection, such as urinary tract infection and the like.
    本文提供的是杂环衍生物化合物和包含这些化合物的药物组合物,其对抑制革兰氏阴性菌的生长非常有用。此外,这些化合物和组合物还可用于治疗细菌感染,如尿路感染等。
  • Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors
    作者:Iain A. Cumming、Sébastien L. Degorce、Anna Aagaard、Erin L. Braybrooke、Nichola L. Davies、Coura R. Diène、Andrew J. Eatherton、Hannah R. Felstead、Sam D. Groombridge、Eva M. Lenz、Yunxia Li、Youfeng Nai、Stuart Pearson、Graeme R. Robb、James S. Scott、Oliver R. Steward、Chengyan Wu、Yafeng Xue、Lanping Zhang、Yanxiu Zhang
    DOI:10.1016/j.bmc.2022.116729
    日期:2022.6
    large basic substituent to a 1-methylcyclopyl group. Subsequent optimisation, facilitated by X-ray crystal structures, allowed identification of preferred substituents at both the pyridone core and pyrazole. Subsequent combinations of optimal groups allowed control of lipophilicity and identification of potent and selective inhibitors of IRAK4 with better in vitro permeability and lower clearance.
    在本文中,我们报告了一系列作为 IRAK4 激酶抑制剂嘧啶吡啶酮的发现。从先前公开的 5-氮杂喹唑啉系列中,我们发现将吡啶环转换为N-取代的吡啶酮产生了一种新的铰链结合支架,它保留了对 IRAK4 的效力。重要的是,羰基的引入与 4-NH 建立了内部氢键,建立了构象锁并允许将大的碱性取代基截断为 1-甲基环基。随后的优化,由 X 射线晶体结构促进,允许在吡啶酮核和吡唑处鉴定优选的取代基。最佳组的后续组合允许控制亲脂性并鉴定具有更好体外渗透性和更低清除率的强效和选择性 IRAK4 抑制剂
  • Bicycloamide Derivative
    申请人:Fukuda Yasumichi
    公开号:US20070265320A1
    公开(公告)日:2007-11-15
    Novel bicycloamide derivatives (general formula (1)) and pharmaceutically acceptable salts thereof effectively inhibit DPP-IV. The bicycloamide derivatives are represented by the general formula (1): Pharmaceutically acceptable salts thereof are also included (Example: (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)).
    新型双环酰胺衍生物(通式(1))及其药学上可接受的盐有效抑制DPP-IV。双环酰胺衍生物由通式(1)表示:其中也包括药学上可接受的盐(例如:(2S,4S)-1- [[(4-基甲酰基双环[2.2.2]辛烷-1-基)基]乙酰基]-4-吡咯烷-2-羧腈)。
查看更多